Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety

被引：0
|
作者：
Fabien Huet
Mariama Akodad
Eran Kalmanovitch
Jerome Adda
Audrey Agullo
Pascal Batistella
Camille Roubille
François Roubille
机构：
[1] Hôpital Arnaud de Villeneuve,Département de Cardiologie
[2] CHU de Montpellier,Department of Internal Medicine and Hypertension
[3] UFR de Médecine,undefined
[4] Université Montpellier 1,undefined
[5] PhyMedExp,undefined
[6] University of Montpellier,undefined
[7] INSERM U1046,undefined
[8] CNRS,undefined
[9] UMR 9214,undefined
[10] Montpellier University Hospital,undefined
来源：
American Journal of Cardiovascular Drugs | 2019年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades. According to recent and promising studies, sacubitril/valsartan (SV) might be efficient in alternative indications in the area of HF with preserved left ventricular ejection fraction, chronic kidney disease, and so on. This review briefly summarizes these promising therapeutic options regarding SV and the potential limits and pitfalls for its use in routine practice (due to cognitive uncertainties).
引用
收藏
页码：1 / 10
页数：9
相关论文
共 50 条
  • [1] Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety
    Huet, Fabien
    Akodad, Mariama
    Kalmanovitch, Eran
    Adda, Jerome
    Agullo, Audrey
    Batistella, Pascal
    Roubille, Camille
    Roubille, Francois
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2019, 19 (01) : 1 - 10
  • [2] Sex Influence on the Efficacy and Safety of Sacubitril/Valsartan
    Vicent, Lourdes
    Ayesta, Ana
    Esteban-Fernandez, Alberto
    Gomez-Bueno, Manuel
    De-Juan, Javier
    Diez-Villanueva, Pablo
    Manuel Iniesta, Angel
    Rojas-Gonzalez, Antonio
    Bover-Freire, Ramon
    Iglesias, Diego
    Garcia-Aguado, Marcos
    Perea-Egido, Jesus A.
    Martinez-Selles, Manuel
    CARDIOLOGY, 2019, 142 (02) : 73 - 78
  • [3] Efficacy and Safety of Sacubitril/valsartan in Patients with Heart Failure
    Alhabeeb, Waleed
    Al Ayoubi, Fakhr
    Hayajneh, Ahmad
    Elshaer, Fayez
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES, 2020, 9 (04): : 11 - 18
  • [4] Safety and efficacy of sacubitril─valsartan in acute heart failure
    Alexandra Le Bras
    Nature Reviews Cardiology, 2019, 16 : 4 - 4
  • [5] Sacubitril/Valsartan and Rhabdomyolysis: Reanalysis of a Potential Safety Signal
    Din, Mian Tanveer Ud
    Minhas, Abdul Mannan Khan
    Muslim, Muhammad Osama
    Wazir, Muhammad Hisham Khan
    Dani, Sourbha S.
    Goel, Sachin S.
    Alam, Mahboob
    Sa, Michel Pompeu
    Seese, Laura
    Hirji, Sameer
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 173 : 145 - 146
  • [6] Safety and efficacy of sacubitril-valsartan in acute heart failure
    Le Bras, Alexandra
    NATURE REVIEWS CARDIOLOGY, 2019, 16 (01) : 4 - 4
  • [7] The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
    Zhao, Cong
    Guo, Yanhong
    Wang, Yulin
    Wang, Liuwei
    Yu, Lu
    Liang, Yan
    Zhai, Zihan
    Tang, Lin
    FRONTIERS IN MEDICINE, 2022, 9
  • [8] The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
    Zhang, Rui
    Sun, Xiaotong
    Li, Ya
    He, Wenzheng
    Zhu, Hongguang
    Liu, Baoshan
    Zhang, Aiyuan
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022, 27
  • [9] Efficacy of Sacubitril/Valsartan in Hypertension
    Malik, Aaqib H.
    Aronow, Wilbert S.
    AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (03) : E322 - E333
  • [10] Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
    Abdin, Amr
    Schulz, Martin
    Riemer, Uwe
    Haderi, Bledar
    Wachter, Rolf
    Laufs, Ulrich
    Bauersachs, Johann
    Kindermann, Ingrid
    Boehm, Michael
    ESC HEART FAILURE, 2022, 9 (06): : 3737 - 3750
12345